Alumis Inc. (ALMS)
ALMSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$6.33
-0.2197 (-3.35%) today
At the close, Nov 10, 4:00 PM ET. After hours $6.48 +1.25%
- Market cap
- $828.39m
- P/E
- –
- EPS, last 4 quarters
- $-3.53
- Dividend yield
- –
- Day range
- $6.27 to $6.67
- 52-week range
- $4.59 to $31.35
- Average volume
- 3.23m
- Previous close
- $6.55
Analysts
8 coveringBuy7 buy, 1 hold, 0 sell
Targets a year out average $29.50, +366.0% from here
Earnings
next estimate $-0.7300Next report Nov 12, 2026
Sep 2025
-15.2%
Dec 2025
+2.1%
Mar 2026
+6.3%
Jun 2026
-11.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $2.07m | $1.93m | $1.74m | $1.66m |
| Gross profit | $2.07m | $1.93m | $1.74m | $1.66m |
| Operating income | -$115.29m | -$96.44m | -$98.41m | -$148.85m |
| Net income | -$110.75m | -$92.93m | -$93.05m | -$142.22m |
Last four quarters: revenue $7.40m, margin -5933.4%, free cash flow –
News
8 latest- Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- Alumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up RTTNews · Oct 9, 2026
- Alumis Reports Positive Phase 3 Data With Envudeucitinib RTTNews · Oct 9, 2026
- Thursday 9/10 Insider Buying Report: ALMS, PRTS BNK Invest · Sep 10, 2026
- HC Wainwright & Co. Upgrades Alumis (ALMS)Fintel · Sep 2, 2026
- Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows PromiseMarketBeat · Sep 1, 2026
- Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges RTTNews · Sep 1, 2026
- Noteworthy Monday Option Activity: DMC, RYAM, ALMSBNK Invest · Aug 24, 2026
The company
Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, its central nervous system penetrant TYK2 inhibitor, with initial development focused on Parkinson's disease and additional neuroinflammatory, neurodegenerative and peripheral immune-mediated disease indications under evaluation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- alumis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.